Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

NJ Economic Development Authority Approves $35-Plus Million for Over 40 Tech and Biotech Companies via Technology Business Tax Certificate Transfer Program

10/7/2016

0 Comments

 
Trenton, NJ — Continuing its commitment to bolster the Garden State’s robust technology ecosystem, the New Jersey Economic Development Authority (EDA) announced on October 3 that 40 New Jersey technology and biotechnology companies have been approved to share over $35 million in Fiscal Year 2017 through the State’s Technology Business Tax Certificate Transfer (NOL) Program.

Administered by the EDA and the New Jersey Department of Treasury's Division of Taxation, this competitive program enables eligible technology and biotechnology companies to sell New Jersey tax losses and/or research and development tax credits to raise non-dilutive cash to finance their growth and operations.

“Entrepreneurs have long touted the NOL Program as critical to the continued growth of their companies,” EDA Chief Executive Officer Melissa Orsen said. “We routinely hear from the industry about the positive effects the program has on providing them with working capital they need to hire new employees or to further their development.”

Agile Therapeutics, a specialty pharmaceutical company in Princeton that focuses on the development of innovative women’s healthcare products, has repeatedly benefited from the NOL Program. The funding has helped Agile Therapeutics support operations during its IPO process.​

“This program has been an important part of our overall funding strategy and we are very appreciative to have been a recipient of this valuable source of non-dilutive financing,” said Al Altomari, President and Chief Executive Officer of Agile. ​

“Proceeds from the program have supported the advancement of our Phase 3 clinical study for our novel once-weekly low dose combined hormonal contraceptive patch that we expect to complete by the end of this year,” Altomari continued.  “Programs like this help make it possible for scientific advancements to take place here in the Garden State and we appreciate the strong support that New Jersey provides to our industry.”

Since the program was established in 1999, more than 500 unique businesses have been approved for awards totaling over $905 million. Sixteen companies are participating in the NOL program for the first time this year.

Twenty-one companies have previously participated in other programs and initiatives offered by the State, such as the Angel Investor Tax Credit Program, the EDA’s semi-annual New Jersey Founders and Funders event, and additional resources available through the EDA’s Commercialization Center for Innovative Technologies (CCIT) in North Brunswick.

The following companies are among the 40 approved. A complete list of NOL award recipients can be found following this article and at http://www.njeda.com/press-room.

ContraVir Pharmaceuticals is new to the NOL Program this year. Located in Edison, the biotechnology company is developing a cure for Hepatitis B through a combination of anti-viral compounds. The company’s pipeline also includes FV-100, which demonstrated the potential to reduce the prevalence of shingles-related pain in a Phase 2 clinical study and is currently in Phase 3 development.

“ContraVir is very excited to participate in this valuable program,” said James Sapirstein, CEO of ContraVir. “The funds will be used to move our clinical programs forward as well as increase our employee footprint in New Jersey. I relocated our company from out of state in order to take part in the NOL Program. We believe it will help to sustain the growth of our company and advance the development of our antiviral therapies.”

Hurel Corporation is another first-time participant. The company provides high-functioning, long-enduring in vitro liver models and microfluidic assay (testing) platforms that improve the predictive reliability of pre-clinical drug development and help reduce costly late-stage attrition in drug-makers' pipelines.

After graduating from CCIT earlier this year, Hurel moved into its own dedicated laboratory space within the Technology Center of New Jersey’s campus in North Brunswick.


“Funding from the NOL will enable us expand our sales and marketing reach, and to continue to develop our prototype microfludic assay platform, trade-named HurelFlow™,” Hurel Chairman and CEO Robert Freedman said.

Vitals provides employers and health plans with cost and quality transparency tools that help consumers shop for health care. Based in Lyndhurst, the company also operates Vitals.com, a website that helps over 11 million consumers each month search for the best quality doctors in their areas.

“It’s a fantastic program and we’ve been active participants in it for a number of years now,” Vitals Chief Financial Officer Bryan Perler said of the NOL Program. “Our ability to sell net operating losses for cash enhances the company’s ability to invest even further in our technology and innovation for the future.”

Watchful Software is a four-year-old technology company headquartered in Marlton and producing data-centric security solutions that help banks and other financial institutions keep customers’ personal data safe from online hackers.

“Watchful Software is participating in the NOL program for the second year as we establish our business,” company CEO Tom Frommack said.

“This ‘pay it forward’ approach has allowed us to accelerate our growth globally and has helped us manage our cash flow enabling us as entrepreneurs to compete and expand,” Frommack added.  “We believe programs of this type help emerging companies expand and represent an enlightened approach to fostering business development in key growth sectors.”

To learn about these resources, visit http://www.njeda.com/tls and follow @NJEDATech on Twitter and LinkedIn.

Acuitive Technologies, Inc.
Advaxis, Inc.
Agile Therapeutics Inc.
Angel Medical, Inc.
Applied Water Management, Inc.
Avlino Inc.
Bellerophon Therapeutics, Inc.
BrilliantLight Power, Inc.
Cancer Genetics, Inc.
CircleBlack, Inc.
Connotate, Inc.
ContraVir Pharmaceuticals, Inc.
CytoSorbents Medical
Edge Therapeutics, Inc.
Elite Laboratories, Inc.
Enteris BioPharma, Inc.
EOS Energy Storage
Flowonix Medical Inc.
Fusar Technologies, Inc
Hemispherx BioPharma
Hurel Corporation
Matinas BioPharma, Inc.
Nanotech Industrial Solutions
Ocean Power Technologies, Inc.
OncoBiologics Inc.
Rive Technology
Roka BioScience, Inc.
Scivantage, Incorporated
Sight Logix, Inc.
Solidia Technologies
Soligenix, Inc.
Svelte Medical Systems, Inc.
TAXIS Pharmaceuticals, Inc
TelVue Corporation
Turnpoint Medical Devices
United Silicon Carbide, Inc.
Vitals
Vydia, Inc.
Watchful Software, Inc.
 
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
222 West State Street
Suite 302
Trenton, NJ 08608
732-729-9619